The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...

Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

(KRON) — Biotech firm Genentech is laying off nearly 100 employees at its South San Francisco headquarters, according to a ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

San Francisco, California–based Genentech, has potent antitumor activity. More than half the patients with advanced and inoperable skin cancer treated with GDC-0449 responded to treatment (New Engl.

Since its founding in San Francisco in 1976, biotechnology pioneer Genentech has helped revolutionize the way doctors treat some of the world’s most complex health challenges, including the ...

A four-year battle over one of the most ubiquitous patents in biotech ended with the US Patent and Trademark Office (USPTO) coming down on Genentech's side. The decision, reached in February ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

Runimotamab is under clinical development by Genentech USA and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, ...